ArticleJournal of molecular histology2026
Silencing soluble epoxide hydrolase protects against myocardial ischemia-reperfusion injury through modulation of the YAP signaling pathway and macrophage polarization.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The objective of this study was to examine the impact of soluble epoxide hydrolase (sEH) on myocardial ischemia–reperfusion (I/R) injury and elucidate the underlying mechanisms. Enzyme-linked immunosorbent assay (ELISA) results revealed that, compared to the Sham group, the concentration of epoxyeicosatrienoic acids (EETs) was significantly reduced in the myocardial tissue of I/R mice, while soluble epoxide hydrolase (sEH) enzyme activity and 14,15-dihydroxyeicosatrienoic acid (14,15-DHET) levels were markedly elevated. Echocardiography, Evans blue/TTC staining, hematoxylin–eosin (HE) staining, and associated indicators demonstrated that the silencing of sEH enhanced cardiac function and ameliorated myocardial tissue damage, leading to a reduction in myocardial infarction size and myocardial cell apoptosis in I/R mice. Furthermore, there was a decrease in the expression of lactate dehydrogenase (LDH), creatine kinase (CK), creatine kinase isoenzyme (CK-MB), and cardiac troponin I (cTnI). Silencing sEH attenuated the inflammatory response induced by I/R injury. It also reduced the release of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. Additionally, it modulated macrophage polarization towards the M2 phenotype. Silencing sEH promoted the YAP signaling pathway, enhancing YAP, CTGF, and Cyr61 expression in I/R injured mouse myocardial tissues and H/R treated cardiomyocytes. Overexpression of YAP can reduce myocardial cell damage induced by H/R, as evidenced by increased cell viability, decreased apoptosis, and lower levels of myocardial injury markers (cTn-I, CK-MB, H-FABP). Additionally, silencing sEH influenced macrophage polarization via the YAP pathway, decreasing TNF-α and IL-6, increasing IL-10, and shifting from M1 to M2 macrophages. Verteporfin treatment reversed these effects. In conclusion, silencing sEH protects against myocardial I/R injury, and the underlying mechanism may be associated with the modulation of YAP signaling pathway activity and the regulation of macrophage polarization.
Indexed as
Identifiers
41872574What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.